Correction To: Sublingual Dexmedetomidine for Agitation Associated With Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

Authors

Leslie Citrome, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA. nntman@gmail.com.
Robert Risinger, BioXcel Therapeutics, Inc., 555 Long Wharf Drive, New Haven, CT, 06511, USA.
Lavanya Rajachandran, BioXcel Therapeutics, Inc., 555 Long Wharf Drive, New Haven, CT, 06511, USA.
Heather Robison, BioXcel Therapeutics, Inc., 555 Long Wharf Drive, New Haven, CT, 06511, USA.

Author Type(s)

Faculty

DOI

10.1007/s12325-022-02350-8

Journal Title

Advances in Therapy

First Page

391

Document Type

Article

Publication Date

1-1-2023

Department

Psychiatry and Behavioral Sciences

Recommended Citation

Citrome, L., Risinger, R., Rajachandran, L., & Robison, H. (2023). Correction To: Sublingual Dexmedetomidine for Agitation Associated With Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. Advances in Therapy, 40 (1), 391. https://doi.org/10.1007/s12325-022-02350-8